眼科指南

订阅

MedSci主页 / 所有栏目 / 眼科指南

2022 SISET立场声明：视网膜静脉阻塞的抗血栓治疗

2022-01-21 意大利血瘀血栓学会 Blood Transfus

视网膜视网膜静脉阻塞

2022年1月，意大利血瘀血栓学会(SISET)发布了视网膜静脉阻塞的抗血栓治疗的立场声明。视网膜静脉阻塞（RVO）是导致视力受损和失明的常见原因，RVO可能与局部（如远视、青光眼）和全身（如高血压、

中文标题：

2022 SISET立场声明：视网膜静脉阻塞的抗血栓治疗

英文标题：

Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET)

发布机构：

意大利血瘀血栓学会

发布日期：

2022-01-21

简要介绍：

2022年1月，意大利血瘀血栓学会(SISET)发布了视网膜静脉阻塞的抗血栓治疗的立场声明。视网膜静脉阻塞（RVO）是导致视力受损和失明的常见原因，RVO可能与局部（如远视、青光眼）和全身（如高血压、糖尿病、吸烟、肥胖和血脂异常）风险因素有关。本文主要依据现有证据和专家建议为RVO患者的临床管理提供指导。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 SISET立场声明：视网膜静脉阻塞的抗血栓治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=cae1c1c002360a38, title=2022 SISET立场声明：视网膜静脉阻塞的抗血栓治疗, enTitle=Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET), guiderFrom=Blood Transfus, authorId=0, author=, summary=2022年1月，意大利血瘀血栓学会(SISET)发布了视网膜静脉阻塞的抗血栓治疗的立场声明。视网膜静脉阻塞（RVO）是导致视力受损和失明的常见原因，RVO可能与局部（如远视、青光眼）和全身（如高血压、, cover=https://img.medsci.cn/2022219/1645281322767_1608702.png, journalId=0, articlesId=null, associationId=431, associationName=意大利血瘀血栓学会, associationIntro=意大利关于血液学的学会，官方网站为意大利语。 出版物《溶栓系统的研究方法:先进研发室的摘要和论文》1993年英语发行。, copyright=0, guiderPublishedTime=Fri Jan 21 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2022年1月，意大利血瘀血栓学会(SISET)发布了视网膜静脉阻塞的抗血栓治疗的立场声明。视网膜静脉阻塞（RVO）是导致视力受损和失明的常见原因，RVO可能与局部（如远视、青光眼）和全身（如高血压、糖尿病、吸烟、肥胖和血脂异常）风险因素有关。本文主要依据现有证据和专家建议为RVO患者的临床管理提供指导。</span></p>, tagList=[TagDto(tagId=2541, tagName=视网膜), TagDto(tagId=10274, tagName=视网膜静脉阻塞)], categoryList=[CategoryDto(categoryId=32, categoryName=眼科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11550, appHits=88, showAppHits=0, pcHits=283, showPcHits=11462, likes=0, shares=14, comments=5, approvalStatus=1, publishedTime=Sun Feb 20 15:34:00 CST 2022, publishedTimeString=2022-01-21, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Sat Feb 19 22:41:08 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 18:21:49 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 SISET立场声明：视网膜静脉阻塞的抗血栓治疗.pdf)])
2022 SISET立场声明：视网膜静脉阻塞的抗血栓治疗.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1226534, encodeId=77bf1226534b8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Wed Jun 15 07:59:49 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201009, encodeId=22a9120100931, content=RVO的病因是多因素的，对因治疗是关键, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Wed Mar 09 19:46:30 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198987, encodeId=ea81119898e32, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Thu Mar 03 10:02:06 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196894, encodeId=7f3d11968942d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220222/09120c6c907546f2833b89808b3b5cb1/5b3e8ffe84c34759b3fa8a8221380b4c.jpg, createdBy=961a2237245, createdName=Sandra欢, createdTime=Thu Feb 24 17:51:38 CST 2022, time=2022-02-24, status=1, ipAttribution=)]
    2022-06-15 245462683

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1226534, encodeId=77bf1226534b8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Wed Jun 15 07:59:49 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201009, encodeId=22a9120100931, content=RVO的病因是多因素的，对因治疗是关键, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Wed Mar 09 19:46:30 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198987, encodeId=ea81119898e32, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Thu Mar 03 10:02:06 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196894, encodeId=7f3d11968942d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220222/09120c6c907546f2833b89808b3b5cb1/5b3e8ffe84c34759b3fa8a8221380b4c.jpg, createdBy=961a2237245, createdName=Sandra欢, createdTime=Thu Feb 24 17:51:38 CST 2022, time=2022-02-24, status=1, ipAttribution=)]
    2022-03-09 rabiby

    RVO的病因是多因素的，对因治疗是关键

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1226534, encodeId=77bf1226534b8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Wed Jun 15 07:59:49 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201009, encodeId=22a9120100931, content=RVO的病因是多因素的，对因治疗是关键, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Wed Mar 09 19:46:30 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198987, encodeId=ea81119898e32, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Thu Mar 03 10:02:06 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196894, encodeId=7f3d11968942d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220222/09120c6c907546f2833b89808b3b5cb1/5b3e8ffe84c34759b3fa8a8221380b4c.jpg, createdBy=961a2237245, createdName=Sandra欢, createdTime=Thu Feb 24 17:51:38 CST 2022, time=2022-02-24, status=1, ipAttribution=)]
    2022-03-03 245462683

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1226534, encodeId=77bf1226534b8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Wed Jun 15 07:59:49 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201009, encodeId=22a9120100931, content=RVO的病因是多因素的，对因治疗是关键, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Wed Mar 09 19:46:30 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198987, encodeId=ea81119898e32, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Thu Mar 03 10:02:06 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196894, encodeId=7f3d11968942d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220222/09120c6c907546f2833b89808b3b5cb1/5b3e8ffe84c34759b3fa8a8221380b4c.jpg, createdBy=961a2237245, createdName=Sandra欢, createdTime=Thu Feb 24 17:51:38 CST 2022, time=2022-02-24, status=1, ipAttribution=)]
    2022-02-24 Sandra欢

    学习了

    0

相关指南

2022 中国台湾专家共识：新生血管性年龄相关性黄斑变性的治疗和延长方案实施的最佳方法和标准

中国眼科相关专家组（统称） · 2022-01-15

临床多焦视网膜电图标准

暂未更新 · 2020-12-30

我国早产儿视网膜病变筛查指南（2014年）

中华医学会眼科学分会 · 2014-12-03